M&A Deal Summary

AbbVie Acquires Landos

On March 25, 2024, AbbVie acquired life science company Landos for 138M USD

Acquisition Highlights
  • This is AbbVie’s 10th transaction in the Life Science sector.
  • This is AbbVie’s 10th largest (disclosed) transaction.
  • This is AbbVie’s 8th transaction in the United States.
  • This is AbbVie’s 1st transaction in Virginia.

M&A Deal Summary
Date 2024-03-25
Target Landos
Sector Life Science
Buyer(s) AbbVie
Deal Type Add-on Acquisition
Deal Value 138M USD
Advisor(s) Jefferies (Financial)
Cooley (Legal)

Target

Landos

Blacksburg, Virginia, United States
Landos is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging its AI-based integrated computational platform, LANCE, the company has identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Its lead product candidate, BT-11, is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. Landos was founded in 2017 and is based in Blacksburg, Virginia.

Search 200,388 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AbbVie

North Chicago, Illinois, United States
Category Company
Founded 2012
Sector Life Science
Employees50,000
Revenue 54.3B USD (2023)
DESCRIPTION
Entrance to Abbvie's office in Lake Forest, Illinois.
Entrance to Abbvie's office in Lake Forest, Illinois.

AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.

DEAL STATS #
Overall 10 of 12
Sector (Life Science) 10 of 12
Type (Add-on Acquisition) 9 of 11
State (Virginia) 1 of 1
Country (United States) 8 of 10
Year (2024) 1 of 3
Size (of disclosed) 10 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-06 Cerevel

Cambridge, Massachusetts, United States

Cerevel is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia, and addiction. Cerevel was formed in 2018 and headquartered in Cambridge, Massachusetts.

Buy $8.7B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-06-27 Celsius Therapeutics

Cambridge, Massachusetts, United States

Celsius Therapeutics is a clinical-stage biotechnology company developing novel medicines for inflammatory disease. The company's lead therapeutic candidate is an anti-TREM1 antibody for treating IBD. Celsius is based in Cambridge, Massachusetts.

Buy $250M
Mergr

Product

Company

Legal